Close Menu

You may find more results for this query on our sister sites: GenomeWeb and 360Dx.

Home › Business, Policy & Funding › Regulatory News & FDA Approvals › European Regulators Recommend Approval of Roche Treatment for HER2-Positive Breast Cancer

European Regulators Recommend Approval of Roche Treatment for HER2-Positive Breast Cancer

Nov 15, 2019
|
staff reporter

NEW YORK – Roche said on Friday that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended approval of its trastuzumab emtansine (Kadcyla) antibody-drug conjugate for the adjuvant treatment of adult patients with HER2-positive early breast cancer who have residual invasive disease, in the breast or lymph nodes, after neoadjuvant taxane-based and HER2-targeted therapy.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Oct
08
Featured Webinar

Novel Applications of RNA-based Precision Oncology: From Drug Tolerability to Immunogenomics

Sponsored by
Genecentric

This webinar, Part 3 of the “Advances in RNA-based Biomarker Development for Precision Oncology” webinar series sponsored by GeneCentric Therapeutics, will discuss novel and emerging applications of RNA-based genomic analysis in precision oncology, form characterizing the tumor microenvironment to informing the development of immuno-oncology treatments.

Oct
14
Featured Webinar

Application of ctDNA Analysis to Detect MRD and Predict Recurrence in Colorectal Cancer

Sponsored by
Inivata

Circulating tumor DNA (ctDNA) can allow clinicians and researchers to better understand which patients are at high risk of recurrence and should be offered intensified chemotherapy or selected for clinical trials.

Oct
15
Featured Webinar

A Comparison of cfDNA Approaches to Guide Targeted Therapy in NSCLC

In non-small cell lung cancer (NSCLC), early detection of emerging resistance mutations such as EGFR T790M is important in order to determine the appropriate targeted therapeutic strategy.

Oct
27
Featured Webinar

The Promise of Liquid Biopsy for Cancer Diagnostics and Therapeutic Monitoring: Are We There Yet?

Sponsored by
LGC SeraCare Life Sciences

This webinar brings together an expert panel of stakeholders in cancer diagnostics and clinical care who will discuss the promise and challenges of liquid biopsy technologies in cancer diagnosis, monitoring, and patient care management.

What's Popular?

In Cancer

  1. Bayer's ATR Inhibitor May Benefit Cancers With ATM Aberrations, Early Data Suggest

  2. Novartis Melanoma Triplet Therapy Failure Raises Questions for Other Combos; Subgroups May Benefit

    Premium

  3. Sema4, Janssen Partner on Patient Identification for Cancer Clinical Trials

  4. Basilea Pharmaceutica to Evaluate FGFR Inhibitor Derazantinib in Gastric Cancer Patients

  5. FDA Expands Patient Access to BioMed Valley's ERK Inhibitor

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.